Ifosfamide in advanced carcinoma of the esophagus: A phase II trial with severe toxicity

Stephen Maxted Ansell, A. S. Alberts, G. Falkson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Seventeen patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (IFOS) 1.5 mg/m2/day intravenously on days 1-5 every 28 days. Mesna was given concurrently at 20% of the IFOS dose prior to and 4 and 8 h after IFOS for urprotection. Toxicity in this trial was severe since life-threatening leukopenia occurred in one patient, Grade 3 nausea and vomiting (necessitating termination of treatment) in two patients, and Grade 3 neurotoxicity (cerebellar dysfunction) in two patients. Two patients developed severe infections (Grade 3). Only four patients experienced no toxicity. One patient had a partial response with a response duration of 8 weeks. The median survival of all patients is 10 weeks. It is concluded that IFOS as given in this trial has limited activity in esophagus carcinoma with severe toxicity.

Original languageEnglish (US)
Pages (from-to)205-207
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume12
Issue number3
StatePublished - 1989
Externally publishedYes

Fingerprint

Ifosfamide
Esophagus
Carcinoma
Mesna
Cerebellar Diseases
Leukopenia
Nausea
Vomiting
Squamous Cell Carcinoma
Survival
Infection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ifosfamide in advanced carcinoma of the esophagus : A phase II trial with severe toxicity. / Ansell, Stephen Maxted; Alberts, A. S.; Falkson, G.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 12, No. 3, 1989, p. 205-207.

Research output: Contribution to journalArticle

@article{ec65a1c70f194f648dfed2fb74ce49f4,
title = "Ifosfamide in advanced carcinoma of the esophagus: A phase II trial with severe toxicity",
abstract = "Seventeen patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (IFOS) 1.5 mg/m2/day intravenously on days 1-5 every 28 days. Mesna was given concurrently at 20{\%} of the IFOS dose prior to and 4 and 8 h after IFOS for urprotection. Toxicity in this trial was severe since life-threatening leukopenia occurred in one patient, Grade 3 nausea and vomiting (necessitating termination of treatment) in two patients, and Grade 3 neurotoxicity (cerebellar dysfunction) in two patients. Two patients developed severe infections (Grade 3). Only four patients experienced no toxicity. One patient had a partial response with a response duration of 8 weeks. The median survival of all patients is 10 weeks. It is concluded that IFOS as given in this trial has limited activity in esophagus carcinoma with severe toxicity.",
author = "Ansell, {Stephen Maxted} and Alberts, {A. S.} and G. Falkson",
year = "1989",
language = "English (US)",
volume = "12",
pages = "205--207",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Ifosfamide in advanced carcinoma of the esophagus

T2 - A phase II trial with severe toxicity

AU - Ansell, Stephen Maxted

AU - Alberts, A. S.

AU - Falkson, G.

PY - 1989

Y1 - 1989

N2 - Seventeen patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (IFOS) 1.5 mg/m2/day intravenously on days 1-5 every 28 days. Mesna was given concurrently at 20% of the IFOS dose prior to and 4 and 8 h after IFOS for urprotection. Toxicity in this trial was severe since life-threatening leukopenia occurred in one patient, Grade 3 nausea and vomiting (necessitating termination of treatment) in two patients, and Grade 3 neurotoxicity (cerebellar dysfunction) in two patients. Two patients developed severe infections (Grade 3). Only four patients experienced no toxicity. One patient had a partial response with a response duration of 8 weeks. The median survival of all patients is 10 weeks. It is concluded that IFOS as given in this trial has limited activity in esophagus carcinoma with severe toxicity.

AB - Seventeen patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (IFOS) 1.5 mg/m2/day intravenously on days 1-5 every 28 days. Mesna was given concurrently at 20% of the IFOS dose prior to and 4 and 8 h after IFOS for urprotection. Toxicity in this trial was severe since life-threatening leukopenia occurred in one patient, Grade 3 nausea and vomiting (necessitating termination of treatment) in two patients, and Grade 3 neurotoxicity (cerebellar dysfunction) in two patients. Two patients developed severe infections (Grade 3). Only four patients experienced no toxicity. One patient had a partial response with a response duration of 8 weeks. The median survival of all patients is 10 weeks. It is concluded that IFOS as given in this trial has limited activity in esophagus carcinoma with severe toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0024371306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024371306&partnerID=8YFLogxK

M3 - Article

C2 - 2499176

AN - SCOPUS:0024371306

VL - 12

SP - 205

EP - 207

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 3

ER -